Using advanced CT imaging to assess patients with acute hemorrhagic stroke

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to collect data on patients with acute hemorrhagic stroke to evaluate the prognostic value of multimodal computed tomography (CT). Participants will undergo three types of CT scans: non-contrast CT, CT angiography, and CT perfusion. The study will follow approximately 10,000 patients for at least one year after discharge to assess various neurological outcomes and complications. The goal is to better understand the pathophysiological changes and improve intervention strategies for these patients.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. age ≥ 18, ≤ 85 years;
2. presence with hemorrhagic stroke

Exclusion Criteria:

1. with a history of previous history of ischemic/hemorrhagic stroke;
2. admission to the emergency department more than a week after symptom onset;
3. serious medical history or existing comorbidities;
4. physical disability due to previous diseases;
5. prior treatment such as external ventricular drainage, digital subtraction angiography and lumbar puncture in other institution;
6. poor original image quality;
7. incomplete follow-up.

Where it's running

• Beijing Tiantan Hospital
  Beijing, Beijing Municipality, China Recruiting

Study contacts

• Study coordinator: Xiaolin Chen, M.D.
• Email: chenxiaolin@bjtth.org
• Phone: 13810624845

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Risk prediction for stroke and cognitive decline in Moyamoya disease and Moyamoya syndrome

  A large multicenter study tests whether combining clinical data, imaging, lab and genetic information can predict who will have stroke or cognitive decline among people with Moyamoya.

  Recruiting Beijing Tiantan Hospital · Beijing, Beijing Municipality and 12 other locations · NCT07894107

• Predicting unruptured brain aneurysm rupture risk with blood pressure variability and 3D changes

  This study follows adults with unruptured intracranial aneurysms who are managed without surgery to see if blood pressure variability and 3D changes in the aneurysm can predict rupture risk using advanced AI.

  Recruiting Beijing Tiantan Hospital · Beijing · NCT07893574

• Ischemic preconditioning to reduce ischemic events in Moyamoya with standard care

  This study tests whether remote ischemic conditioning can lower stroke risk for adults with Moyamoya disease who are receiving standard medical care.

  Recruiting Beijing Tiantan Hospital · Beijing, Beijing Municipality · NCT07889531

• Rapid CSF ctDNA Test and Treatment Monitoring for Primary CNS Lymphoma

  This study tests whether CSF circulating tumor DNA can quickly diagnose primary CNS lymphoma and monitor response to treatment in adults.

  Recruiting Beijing Tiantan Hospital · Beijing, Beijing Municipality · NCT07851363

• Biobank Registry for Primary CNS Lymphoma in China

  This study will collect and register a long-term, multimodal biobank from adults with PCNSL to support future research, using patients with similar diagnoses as controls and healthy volunteers for comparison.

  Recruiting at 3 sites Beijing Tiantan Hospital · Beijing, Beijing Municipality and 2 other locations · NCT07842835

• Zanubrutinib plus Lenalidomide for frail elderly with newly diagnosed PCNSL

  This study tests whether a combination of zanubrutinib and lenalidomide can help frail elderly patients with newly diagnosed primary CNS lymphoma.

  Recruiting Phase 2 Beijing Tiantan Hospital · Beijing, Beijing Municipality · NCT07839247

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.